Edwards Extraordinary Items vs Selling General Administrative Analysis
EW Stock | USD 90.11 0.05 0.06% |
Edwards Lifesciences financial indicator trend analysis is much more than just examining Edwards Lifesciences Corp latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Edwards Lifesciences Corp is a good investment. Please check the relationship between Edwards Lifesciences Extraordinary Items and its Selling General Administrative accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.
Extraordinary Items vs Selling General Administrative
Extraordinary Items vs Selling General Administrative Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Edwards Lifesciences Corp Extraordinary Items account and Selling General Administrative. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Edwards Lifesciences' Extraordinary Items and Selling General Administrative is 0.84. Overlapping area represents the amount of variation of Extraordinary Items that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Edwards Lifesciences Corp, assuming nothing else is changed. The correlation between historical values of Edwards Lifesciences' Extraordinary Items and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Extraordinary Items of Edwards Lifesciences Corp are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Extraordinary Items i.e., Edwards Lifesciences' Extraordinary Items and Selling General Administrative go up and down completely randomly.
Correlation Coefficient | 0.84 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Extraordinary Items
Selling General Administrative
Most indicators from Edwards Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Edwards Lifesciences Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. At this time, Edwards Lifesciences' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 0.36 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 169.1 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 4.0B | 4.3B | 4.6B | 4.9B | Total Revenue | 5.2B | 5.4B | 6.0B | 6.3B |
Edwards Lifesciences fundamental ratios Correlations
Click cells to compare fundamentals
Edwards Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edwards Lifesciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 6.5B | 7.2B | 8.5B | 8.3B | 9.4B | 9.8B | |
Other Current Liab | 6.4M | 39.3M | 3.9M | 311M | 15.2M | 14.4M | |
Total Current Liabilities | 902.4M | 893.9M | 1.0B | 1.0B | 1.2B | 1.3B | |
Total Stockholder Equity | 4.1B | 4.6B | 5.8B | 5.8B | 6.7B | 7.0B | |
Property Plant And Equipment Net | 1.1B | 1.5B | 1.6B | 1.7B | 1.8B | 1.9B | |
Retained Earnings | 3.7B | 4.6B | 6.1B | 7.6B | 9.0B | 9.4B | |
Non Current Assets Total | 3.5B | 4.1B | 5.3B | 5.2B | 5.3B | 5.6B | |
Non Currrent Assets Other | 101.8M | 119.6M | 110.8M | 299.1M | 463.7M | 486.9M | |
Cash And Short Term Investments | 1.5B | 1.4B | 1.5B | 1.2B | 1.6B | 1.7B | |
Net Receivables | 599.1M | 602.8M | 664.9M | 699.1M | 836.9M | 878.7M | |
Good Will | 1.2B | 1.2B | 1.2B | 1.2B | 1.3B | 688.6M | |
Common Stock Shares Outstanding | 636.6M | 631.9M | 631.2M | 624.2M | 609.4M | 550.8M | |
Liabilities And Stockholders Equity | 6.5B | 7.2B | 8.5B | 8.3B | 9.4B | 9.8B | |
Non Current Liabilities Total | 1.4B | 1.8B | 1.6B | 1.5B | 1.4B | 800.7M | |
Inventory | 640.9M | 802.3M | 726.7M | 875.5M | 1.2B | 1.2B | |
Other Current Assets | 168M | 208.2M | 237.1M | 195.9M | 239.3M | 251.3M | |
Other Stockholder Equity | 344.6M | (466M) | (716.5M) | (2.2B) | (2.8B) | (2.6B) | |
Total Liab | 2.3B | 2.7B | 2.7B | 2.5B | 2.6B | 1.4B | |
Property Plant And Equipment Gross | 1.1B | 1.5B | 1.6B | 1.7B | 2.7B | 2.8B | |
Total Current Assets | 3.0B | 3.1B | 3.2B | 3.1B | 4.0B | 4.2B | |
Accumulated Other Comprehensive Income | (156M) | (161.1M) | (157.7M) | (254.9M) | (242.8M) | (230.7M) | |
Short Long Term Debt Total | 593.8M | 678.8M | 694.9M | 690.3M | 691.3M | 486.4M | |
Other Liab | 784.1M | 1.1B | 969.6M | 797.6M | 917.2M | 963.1M | |
Net Debt | (500.3M) | (488.3M) | (172.5M) | (77.7M) | (449.1M) | (426.6M) | |
Accounts Payable | 180.4M | 196.5M | 204.5M | 201.9M | 201.4M | 139.5M | |
Cash | 1.2B | 1.2B | 862.8M | 769M | 1.1B | 1.2B | |
Other Assets | 274M | 1.2B | 357.5M | 783.1M | 900.6M | 945.6M | |
Long Term Debt | 594.4M | 595M | 595.7M | 596.3M | 597M | 425.6M | |
Common Stock Total Equity | 218.1M | 636.4M | 642M | 646.3M | 743.2M | 780.4M | |
Short Term Debt | 598M | 0.0 | 25.5M | 27.2M | 24.9M | 23.7M | |
Intangible Assets | 336.5M | 331.4M | 323.6M | 285.2M | 428.4M | 449.8M | |
Common Stock | 218.1M | 636.4M | 642M | 646.3M | 650.5M | 683.0M | |
Property Plant Equipment | 1.1B | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B | |
Treasury Stock | (1.0B) | (1.3B) | (1.9B) | (2.4B) | (2.2B) | (2.1B) | |
Short Term Investments | 337.8M | 219.4M | 604M | 446.3M | 500.5M | 382.6M | |
Net Tangible Assets | 2.9B | 3.4B | 4.3B | 4.4B | 5.0B | 5.3B | |
Retained Earnings Total Equity | 3.7B | 4.6B | 6.1B | 7.6B | 8.7B | 9.2B | |
Capital Surpluse | 1.6B | 1.4B | 1.7B | 2.0B | 2.3B | 1.2B | |
Long Term Investments | 585.5M | 801.6M | 1.8B | 1.2B | 583.9M | 582.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Edwards Stock analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
CEOs Directory Screen CEOs from public companies around the world | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.036 | Earnings Share 2.32 | Revenue Per Share 10.151 | Quarterly Revenue Growth 0.095 | Return On Assets 0.1205 |
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.